CTNM
Contineum Therapeutics Inc
$
10.945
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.700
Open
10.970
VWAP
10.83
Vol
687.89K
Mkt Cap
319.40M
Low
10.210
Amount
7.45M
EV/EBITDA(TTM)
--
Total Shares
29.18M
EV
137.00M
EV/OCF(TTM)
--
P/S(TTM)
--
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
--
--
-0.623
+0.54%
--
--
-0.633
+2.15%
--
--
-0.407
-27.3%
Estimates Revision
The market is revising Downward the revenue expectations for Contineum Therapeutics, Inc. (CTNM) for FY2025, with the revenue forecasts being adjusted by -16.67% over the past three months. During the same period, the stock price has changed by 10.11%.
Revenue Estimates for FY2025
Revise Downward
-16.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-8.13%
In Past 3 Month
Stock Price
Go Up
+10.11%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast CTNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTNM is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.945
Low
20.00
Averages
24.00
High
29.00
Current: 10.945
Low
20.00
Averages
24.00
High
29.00
RBC Capital
Brian Abrahams
Outperform
to
NULL
downgrade
$25 -> $22
2025-11-21
New
Reason
RBC Capital
Brian Abrahams
Price Target
$25 -> $22
2025-11-21
New
downgrade
Outperform
to
NULL
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Contineum to $22 from $25 but keeps an Outperform rating on the shares. The company reported that the phase 2 rrMS VISTA study of M1 antagonist PIPE-307 did not meet its primary or secondary endpoints, but while this removes the potential for upside optionality, the firm had always viewed this trial and indication as high risk, the analyst tells investors in a research note. RBC adds that the decision should not meaningfully impact the potential for '307's success in depression, and the program's core valuation remains predicated on their other asset '791's promise in IPF, or idiopathic pulmonary fibrosis.
Leerink
initiated
$20
2025-09-25
Reason
Leerink
Price Target
$20
2025-09-25
initiated
Reason
Leerink initiated coverage of Contineum with an Outperform rating and $20 price target.
William Blair
analyst
Outperform
initiated
$23.26
2025-06-19
Reason
William Blair
analyst
Price Target
$23.26
2025-06-19
initiated
Outperform
Reason
William Blair initiated coverage of Contineum with an Outperform rating. Contineum is a clinical-stage biotech developing small-molecule therapeutics for indications in the neuroinflammation and immunology space developing PIPE-791, a wholly owned asset for the treatment of idiopathic pulmonary fibrosis, progressive forms of multiple sclerosis and chronic pain indications, notes the analyst, who sees a fair value of $23.26 per share.
Jones Trading
Debanjana Chatterjee
Strong Buy
Initiates
$23
2025-03-13
Reason
Jones Trading
Debanjana Chatterjee
Price Target
$23
2025-03-13
Initiates
Strong Buy
Reason
Morgan Stanley
Jeffrey Hung
Buy
Initiates
$25
2025-03-07
Reason
Morgan Stanley
Jeffrey Hung
Price Target
$25
2025-03-07
Initiates
Buy
Reason
Morgan Stanley assumed coverage of Contineum with an Overweight rating. The firm believes PIPE-791 is competitive in idiopathic pulmonary fibrosis given its optimized pharmacokinetics and for PIPE-791 for primary progressive multiple sclerosis it believes Phase 1b topline results in Q2 can de-risk the Phase 2 study, the analyst tells investors.
Baird
Joel Beatty
Buy
Maintains
$32 → $16
2025-03-07
Reason
Baird
Joel Beatty
Price Target
$32 → $16
2025-03-07
Maintains
Buy
Reason
Baird lowered the firm's price target on Contineum to $16 from $32 and keeps an Outperform rating on the shares. The firm said its Phase 2 results in relapsing-remitting MS is on track for the second half of 2025.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Contineum Therapeutics Inc (CTNM.O) is -5.19, compared to its 5-year average forward P/E of -6.69. For a more detailed relative valuation and DCF analysis to assess Contineum Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.69
Current PE
-5.19
Overvalued PE
-3.21
Undervalued PE
-10.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.85
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-8.48
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
52.13
Current PS
0.00
Overvalued PS
82.54
Undervalued PS
21.72
Financials
Annual
Quarterly
FY2025Q3
N/A
Total Revenue
FY2025Q3
YoY :
+15.09%
-14.93M
Operating Profit
FY2025Q3
YoY :
+24.59%
-12.79M
Net Income after Tax
FY2025Q3
YoY :
+12.50%
-0.45
EPS - Diluted
FY2025Q3
YoY :
+96.69%
-12.30M
Free Cash Flow
FY2025Q3
N/A
Gross Profit Margin - %
FY2025Q3
N/A
FCF Margin - %
FY2025Q3
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
148.3K
Volume
1
0-12
Months
75.4K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTNM News & Events
Events Timeline
2025-11-20 (ET)
2025-11-20
16:09:09
Contineum Phase 2 VISTA trial fails to achieve primary and secondary objectives.
2025-10-30 (ET)
2025-10-30
16:21:00
Contineum announces Q3 EPS of 45 cents, falling short of consensus estimate of 46 cents.
2025-09-18 (ET)
2025-09-18
08:51:13
Contineum reveals key findings from PIPE-791 trial
Sign Up For More Events
Sign Up For More Events
News
9.0
11-21Yahoo FinancePinnedContineum Stock Declines Following Unsuccessful Phase 2 PIPE-307 Trial for Multiple Sclerosis Efficacy
9.0
11-21BenzingaPinnedContineum Therapeutics' Multiple Sclerosis Trial Falls Short, Yet Analyst Believes Other Assets Will Enhance Value
4.0
09-25BenzingaLululemon Analyst Changes Stance; Check Out Thursday's Top 3 Downgrades
Sign Up For More News
People Also Watch
HYAC
Haymaker Acquisition Corp 4
11.330
USD
-0.09%
VMD
Viemed Healthcare Inc
6.660
USD
+4.88%
NATH
Nathan's Famous Inc
97.330
USD
+3.70%
MPX
Marine Products Corp
8.440
USD
+2.93%
MVIS
MicroVision Inc
0.938
USD
+2.29%
LFVN
LifeVantage Corp
6.430
USD
+1.90%
VACH
Voyager Acquisition Corp
10.510
USD
0.00%
FSBW
FS Bancorp Inc
40.300
USD
+3.28%
XOMA
Xoma Royalty Corp
31.750
USD
-0.25%
FAQ
What is Contineum Therapeutics Inc (CTNM) stock price today?
The current price of CTNM is 10.945 USD — it has decreased -10.43 % in the last trading day.
What is Contineum Therapeutics Inc (CTNM)'s business?
What is the price predicton of CTNM Stock?
What is Contineum Therapeutics Inc (CTNM)'s revenue for the last quarter?
What is Contineum Therapeutics Inc (CTNM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Contineum Therapeutics Inc (CTNM)'s fundamentals?
How many employees does Contineum Therapeutics Inc (CTNM). have?